PTC
CRSP icon

Philadelphia Trust Company’s CRISPR Therapeutics CRSP Stock Holding History

Philadelphia Trust Company’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,750
Closed -$243K – 260
2025
Q3 		$243K Sell
3,750
-46,500
-93% -$2.67M 0.02% 223
2025
Q2 		$2.44M Buy
+50,250
New +$1.94M 0.19% 73

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
GP
GSK plc London $599M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Philadelphia Trust Company's CRSP Position: Q4 2025 in Review

Philadelphia Trust Company sold out of CRISPR Therapeutics (CRSP) in Q4 2025, closing a stake of 3,750 shares — an estimated $243K sold.

Philadelphia Trust Company first reported a position in CRSP in Q2 2025 and held it in 2 quarters. The position peaked at $2.44M in Q2 2025. 479 funds tracked by Wall St. Rank hold CRSP as of Q4 2025.

  • Philadelphia Trust Company reported no remaining CRISPR Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Philadelphia Trust Company sold 3,750 CRISPR Therapeutics shares in Q4 2025, an estimated $243K.
  • Philadelphia Trust Company first reported a position in CRISPR Therapeutics in Q2 2025 and held it in 2 quarters.
  • Philadelphia Trust Company's CRISPR Therapeutics position peaked at $2.44M in Q2 2025.
  • 479 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2025.

Based on Philadelphia Trust Company's 13F filing for Q4 2025, filed 12 Feb 2026.